Bayer's Weinand On Broadening Value-Based Pricing Views
Executive Summary
Bayer's pharma head Dieter Weinand talks about his biggest issues with current value-based pricing assessments for new drugs and how companion diagnostics will pave the way to easier pricing of oncology therapies.
You may also be interested in...
US Outcomes-Based Contracts In Oncology? CAR-T Could Be Case Study
Groundbreaking but potentially very expensive new CAR-T treatments for cancer could be suited to outcomes-based contracts, Harvard Pilgrim's Sherman suggests.
Bayer Bets On Oncology Pipeline, Vows To Increase 2017 R&D Budget
Bayer has launched an internal oncology R&D unit to speed up development of its pipeline cancer therapies and ensure the company is first to market with its late-stage treatment candidates, head of pharma Dieter Weinand told Scrip on the sidelines of the pharma's annual results conference.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.